Concepedia

Author

William Shingler

Oxford BioMedica (United Kingdom)ORCID

Also Known As

M. I. Sharif, W H Shingler, W. H. Shingler, W. Shingler, W.H. Shingler, Wendy Shingler, William H Shingler, William H. Shingler, William Shingler

39

Publications

936

Citations

13

H-Index

29

Concepts

All Affiliations

Oxford BioMedica (United Kingdom)The Christie HospitalMemorial HermannRoyal Statistical SocietySt James's University Hospital
WS

About

William Shingler is an author at Oxford BioMedica (United Kingdom) specializing in immunology, medicine, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

396

2

Immunology

7

7

396

3

Pathology

3

3

203

4

Cell Biology

1

1

91

5

Pharmacology

1

1

43

William Shingler

×

13

Publications

885

Citations

13

H-Index

YearCitations

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman,

Clinical Cancer Research

2010

195

CD14-dependent clearance of apoptotic cells by human macrophages: the role of phosphatidylserine

Andrew Devitt, Sarah Pierce, Ceri Oldreive,

Cell Death and Differentiation

2003

91

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses

Richard Harrop, Noel Drury, William Shingler,

Clinical Cancer Research

2007

90

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

Richard Harrop, Noel Drury, William Shingler,

Cancer Immunology Immunotherapy

2007

85

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)

Robert J. Amato, William Shingler, Madusha Goonewardena,

Journal of Immunotherapy

2009

76

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Howard L. Kaufman, Bret Taback, William H. Sherman,

Journal of Translational Medicine

2009

74

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

Robert J. Amato, William Shingler, Stuart Naylor,

Clinical Cancer Research

2008

62

Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α

Robert E. Hawkins, Catriona Macdermott, Alaaeldin Shablak,

Journal of Immunotherapy

2009

43

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Mark R. Middleton, Neil Steven, Thomas Evans,

Journal of Clinical Oncology

2016

43

Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients

Richard Harrop, William Shingler, Michelle Kelleher,

Journal of Immunotherapy

2010

36

Page 1